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Abstract: The manipulation of the immune system through the administration of a vaccine 
to direct an effective and long-lasting immune response against breast cancer (BC) cells is an 
attractive strategy. Vaccines would have several theoretical advantages over standard therapies, 
including low toxicities, high specificity, and long-lasting efficacy due to the establishment of 
immunological memory. However, BC vaccines have failed to demonstrate meaningful results 
in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-
escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex 
immunologic response involving multiple immune effectors such as cytotoxic and antibody-
secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients 
with large tumor burdens and metastatic disease, combining vaccines with other strategies, such 
as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase 
the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing 
on suitable targets and innovative strategies. We report results of most recent trials investigating 
active immunotherapy in BC and provide possible future perspectives in this field of research.
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Introduction
Recently, advances in early diagnosis and more effective treatments have reduced the 
mortality rate due to breast cancer (BC).1 However, despite this progress, BC remains a 
leading cause of death in the female population worldwide.2 In this scenario, manipulat-
ing the immune system to direct an effective and long-term immune response against 
BC cells through the administration of a vaccine is an attractive strategy. Tumor vac-
cination would have several theoretical advantages over standard therapies. First, the 
ideal tumor vaccine would induce potent and durable immune reactions against a broad 
spectrum of tumor antigens. It could be easily administered and manufactured, with 
modest side effects typical of conventional chemotherapies. Moreover, it would prevent 
further tumor recurrences, due to the establishment of persistent immune memory. 
At present, however, active immunotherapeutic strategies against cancer have failed 
to fulfill the above expectations in clinical trials.3 This reflects the intrinsic difficulty 
in finding optimal targets for a cancer vaccine, the most effective type of vaccination, 
route of  administration, and the most immunologically favorable setting of disease 
(eg, low tumor burden, not heavily pretreated patients). Most importantly, it reflects 
the difficulty in breaking the complex immune-escaping mechanisms developed by 
cancer cells.4 The aim of this review is to summarize recent advances in BC active 
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immunotherapy, to address recent results from clinical  trials, 
and to provide possible future perspectives in this field of 
research.
Targets and strategies of BC 
vaccines
It has been well established that the immune system plays 
a role in controlling tumor growth, and adaptive immunity 
is the main mediator of “spontaneous” regression of certain 
types of cancers.5,6 The immune system has the ability to 
recognize several types of antigens expressed on tumor cell 
surfaces, namely the tumor-associated antigens (TAAs).7 
TAAs are presented to immune system effectors such as 
T-cells by the tumor itself, through the major histocompat-
ibility complex (MHC) or, more likely, by antigen present-
ing cells (APCs), in particular macrophages and dendritic 
cells (DCs).7 These cells are essential in processing antigens 
into immunogenic peptides and presenting them to naive 
T-cells through the MHC complex. Through a complex and 
regulated system of co-activator and inhibitory molecules 
expressed on the cell surface, these cells play an essential role 
in priming T lymphocytes and activating an immunogenic 
response against specific targets.8 The presence of tumor-
infiltrating lymphocytes has been correlated with better 
prognosis in several types of cancers.9,10 However, tumor cells 
often develop the ability to circumvent the surveillance of the 
immune system.11 In the tumor microenvironment, molecules 
such as vascular endothelial growth factor, transforming 
growth factor (TGF)-β, and interleukins are abundant and 
both actively downregulate the immune function and pro-
mote tumor progression, invasion, and metastasis.12 In addi-
tion, tumor cells can directly downregulate T-cell function 
through expression of transmembrane inhibitory molecules 
such as FasL or B7-H1/PD-L1 or, indirectly, by promot-
ing functionally suppressive CD4+FoxP3+ T  lymphocyte 
(TReg) function.13,14 Finally, cancer cells can modulate 
expression or mask TAAs, reducing their availability and 
presentation to immune effectors.15 All these mechanisms 
can therefore lead to altered DC and T-cell function, and, 
as final result, to impaired immune response against tumor 
cells. Immune-escaping mechanisms are particularly active 
in epithelial cancers such as BC.16 However, some degree 
of immune response against TAAs can be demonstrated in 
BC patients.17–19 This has prompted researchers to develop 
active immunotherapies to therapeutically amplify these 
weak responses against known immunogenic BC antigens. 
In fact, the aim of an effective therapeutic vaccine is to break 
peripheral tolerance and activate low-affinity T-cells that 
were not eliminated during selection in thymus.20 A number 
of breast TAAs have been recognized and described so 
far (Table 1). Among them, human epithelial growth fac-
tor receptor 2 (HER2), carbohydrate antigens, telomerase 
reverse transcriptase (hTERT), and mucin-1 (MUC-1) have 
received the greatest attention for vaccine formulations7 
and have been tested in clinical trials. In order to produce 
an effective vaccine, an antigen or a pool of antigens (as for 
whole-tumor-cell vaccines) should be delivered through an 
appropriate formulation. Activation of the immune system 
could be enhanced by including adjuvant compounds, and 
appropriate monitoring techniques should be prompted to 
assess the immunologic response.21 Recently, new tech-
nologies such as the use of nanoparticles and liposome 
 formulations, which may improve efficacy of vaccines have 
received great attention, and preclinical studies with interest-
ing results have been published.22–24 Indeed, various vaccine 
formulations have been tested so far, but none of these was 
shown to be superior in all situations. Distinct vaccination 
platforms engage different aspects of the antitumor immune 
response and each has its own pros and cons, as briefly sum-
marized in Table 2.
Peptide-based vaccination
Peptide-based vaccines aim at inducing immune responses 
(including antibodies, cytotoxic T lymphocytes [CTLs], and 
helper T-cells) using antigenic epitopes derived from TAAs. 
Table 1 Main breast cancer TAAs
Target Description
Carcinoembryonic  
antigen
Glycoprotein involved in cell adhesion, 
normally expressed during fetal development
Human epithelial  
growth factor  
receptor 2
Growth factor receptor belonging to human 
epithelial growth factor receptor family 
Overexpressed in 20%–30% of breast cancer 
cells, correlates with adverse prognosis
MUC-1 Membrane glycoprotein involved in 
immunologic and cell signaling functions 
Overexpressed in 70% of breast cancers
hTeRT Component of the telomerase complex,  
a ribonucleoprotein that maintain chromosome 
integrity during cell proliferation and division
p53 Tumor suppressor protein, involved in cell 
cycle regulation and DNA damage repair 
Mutated in 20% of breast cancers
Mammaglobin-A Glycoprotein overexpressed in 80%  
of metastatic breast cancers
Cancer testis antigens  
(NY-eso-1, MAGe,  
BAGe, and GAGe)
Proteins expressed in normal germ cells of the 
testis and embryonic ovaries and in certain 
types of cancer
Abbreviations: TAAs, tumor-associated antigens; hTeRT, telomerase reverse 
transcriptase; MUC-1, mucin-1.
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Many of the first cancer vaccine strategies focused on 
 inducing tumor-specific CD8+ cells with MHC class I 
restricted short peptides.25–27 It is now clear that these CD8+ 
T-cell responses are typically weak and short-lived.25,28 Fur-
ther studies have clarified that triggering the CD4+ T-cell 
response is critical for maximizing tumor immunity, as it 
both optimizes the CD8+ T-cell response and supports the 
humoral antitumor immune response.29 Thus, researchers 
have focused on studying peptide-based vaccines that are 
able to trigger both CD4+ and CD8+ responses, using longer 
peptides or mixtures of epitopes.30 Peptide vaccines have 
several potential advantages, which include easy manu-
facturing, easily evaluable immunological response, and 
low expected toxicities. These advantages have made the 
peptide-based vaccination widely studied and employed in 
clinical trials. However, this strategy presents some objec-
tive limitations. First, to be effective, peptide vaccines often 
require co-administration of an immunological adjuvant. 
Adjuvants play an important role in favoring recruitment 
and efficient stimulation of immune effectors. Identification 
of an even more efficient adjuvant for a given vaccine is 
crucial for the effectiveness of the formulation and has 
been the object of intense research. Second, most of the 
peptide-based vaccines tested are restricted to HLA-A2. 
This limits the number of potentially benefiting patients. 
Third, although easily monitored, immune response is 
directed against one or a few epitopes, possibly reducing 
the effectiveness of response and favoring mechanisms of 
immune escape. Finally, we should consider population- 
and patient-specific variability in antigen processing and 
presentation, which could affect the effectiveness of such 
a strategy.31
Table 2 Current vaccine platforms
Vaccine platform Strengths Possible limitations
Peptide-based vaccines easily produced and delivered 
Low toxicities 
easy to monitor immunologic response
Able to elicit mainly one compartment of immunological  
response (cytotoxic or humoral) 
Require boosts inoculation to maintain immunological memory 
HLA-restricted 
Require suitable adjuvant 
Response restricted to one or few epitopes
DC-based vaccines Not HLA restricted 
Capable to elicit immunological memory,  
humoral and cytotoxic response
Technically challenging 
Requires expansion, maturation, and activation of DCs
DNA-based vaccines Can be produced on larger scales 
Can elicit both humoral and cytotoxic  
compartments
Risk of toxicities 
Low efficiency of naked DNA or plasmids 
Difficulties in finding suitable vectors
whole cell-based vaccines Can elicit a response against broad  
spectrum of antigens 
Not HLA-restricted
Difficult to monitor response 
Risk of toxicities and autoimmunity 
Requires cell manipulation to be immunogenic
Abbreviations: HLA, human leukocyte antigen; DC, dendritic cell.
DNA-based vaccination
The principle of this approach is based on the  assumption 
that the DNA encoding for a given TAA can be taken by 
APCs, translated into protein, and finally processed for 
presentation. DNA can be delivered naked or complexed 
with other molecules. Frequently, the most used vectors are 
viruses that are able to efficiently transfect target cells.32,33 
Recently, new technologies such as nanoparticles and lipo-
some preparations have been successfully employed to deliver 
DNA vaccines.34–36 A large body of evidence supports the 
idea that stimulating a coordinated immune response, involv-
ing cellular, humoral, and innate immune effectors (natural 
killer cells and macrophages), most effectively mediates 
tumor rejection.37,38 DNA vaccines, because of their unique 
mechanisms of action, could stimulate a more “physiologic” 
immune response against antigens and could be produced 
on a larger scale. However, finding an effective vector can 
be challenging.
Dendritic cells-based vaccination
DCs are the most important APCs. They naturally express 
high levels of MHC molecules, co-stimulatory proteins, 
and cytokines.39,40 Autologous DCs can be modified by 
fusion with cancer cells by pulsing with peptides or by 
transfection to express tumor antigens.41 DC vaccination 
represents one of the most intriguing platforms in cancer 
vaccines. In fact, DCs are able to stimulate both class I and 
class II responses and can be further modified in order to 
co-express co-stimulatory molecules, and responses can 
be directed against multiple targets. This type of platform 
has been successfully employed and approved for clinical 
use in castration-resistant prostate cancer.42,43 However, this 
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vaccine platform remains  technically challenging due to the 
uncertainty related to the optimal route of administration and 
expansion, maturation, and/or activation of DC cells, which 
is not easily achievable ex vivo and, as a result, this limits 
larger scale manufacturing.
whole cells-based vaccination
Another potential approach is immunizing the patient 
with whole tumor cells, derived from the patient herself 
(autologous) or from cell-line cultures (allogeneic). These 
vaccines have been shown to induce antigen-specific T-cell 
responses. However, more frequently, tumor cells act as 
antigenic pool for in vivo or ex vivo APCs presentation. 
To enhance immunological response, tumor cells can be 
genetically modified to express co-stimulatory molecules 
or cytokines.44 Theoretical advantages of such approach 
comprise providing a pool of tumor antigens, generat-
ing immune responses to more than one antigen, and 
thereby possibly overcoming the tumor antigen loss.45 
Moreover, this could lead to a more “complex” response, 
involving both CD4+ and CD8+ T-cells, against different 
antigens. Potential drawbacks may be the triggering of 
autoimmunity and difficulties in monitoring the conse-
quent immunologic response that may be directed against 
unknown TAAs.46
Anti-HER2 vaccines
HER2 is a protein receptor with tyrosine kinase activity 
belonging to the human epidermal growth factor receptor 
family overexpressed in 25%–30% of BC.47 HER2 is effec-
tively targeted by a number of new-generation therapies, 
such as the monoclonal antibodies trastuzumab, pertuzumab, 
or T-DM1,48–50 and small tyrosine kinase inhibitors such as 
Lapatinib, Neratinib, and Afatinib.51–53 HER2 is a suitable 
target for BC vaccines, and several investigations have shown 
that some patients develop spontaneous anti-HER2-specific 
immunity with high levels of both cellular and humoral 
response.17,54
The largest body of data resulting from anti-HER2 vac-
cinations derives from clinical trials employing peptide-based 
vaccines in different clinical settings. The most studied 
HER2-derived peptide in clinical trials is E75 (HER2 amino 
acids [aa] 369–377) derived from the extracellular domain 
of HER2 and characterized by HLA-A2 restriction.55 In the 
initial studies, E75 was demonstrated to be safe and capable 
of inducing peptide-specific CD8+ response. The majority of 
patients enrolled in these pivotal studies had breast or ovarian 
cancer and were vaccinated with  increasing doses of vaccine 
administered monthly, with up to six immunizations.17,25,26,56,57 
In a retrospective analysis aimed at evaluating long-term 
outcome of BC patients enrolled in these early trials, it was 
shown that 21 out of 52 (40%) identified patients were alive at 
the time of analysis (median follow-up [FU] of 112 months).58 
Six out of eight (75%) evaluable patients had persistent 
T-cell immunity versus immunizing HER2 peptides. More-
over, seven out of eight evaluable patients (88%) developed 
 T-cell-specific immunity against HER2 epitopes other than the 
one used for immunization, likely due to epitope spreading. 
These data showed that E75 was able to induce effective and 
long-lasting immunologic responses. Given the encouraging 
results, E75 was tested in two larger Phase II clinical trials in 
an adjuvant setting.59 A total of 195 women with HER2 posi-
tive (with score $1 by immunohistochemistry) were included 
(100 lymph-node positive, 95 lymph-node negative) after 
completion of a standard course of surgery, chemotherapy, and 
radiotherapy.60 The final results of this study have been very 
recently reported.61 The vaccine was administered with gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF) for 
up to six immunizations, and 49% of patients received booster 
inoculations. At 5 years, the disease-free survival (DFS) rate 
for vaccinated patients was 89.7% versus 80.2% for controls 
(P=0.08).62 Although not statistically significant, vaccination 
was associated with a 48% reduction of relative risk of recur-
rence. Interestingly, among the node-positive population, 
benefits of vaccination were shown to be larger. In fact, the 
24-month DFS rate was 90.2% for vaccinated patients and 
79.1% for controls (P=0.13), with a relative reduction of risk 
for recurrence of 53%. Interestingly, patients expressing low 
levels of HER2 (immunohistochemistry 1 or 2+) had more 
robust immunologic response,63 and in this population the 
DFS rate was improved at 5 years of FU,64 with the DFS rate 
of 88.1% in vaccinated patients  versus 77.5% in controls 
(P=0.16). In contrast, in patients whose tumors overexpressed 
HER2, the DFS rate was 90.3% for vaccinated patients versus 
83.3% for controls (P=0.44). Of 30 vaccinated patients who 
had HER2-overexpressing tumors, only 12 patients received 
trastuzumab before vaccination, and none of these patients 
had recurrences. Because of the trial design, not all patients 
received the vaccine dose that was subsequently determined 
to be optimal. Moreover, a booster inoculation was adminis-
tered in 53 patients (49%). Intriguingly, among the patients 
who received booster inoculations the DFS rate at 5 years 
was 95.2% (P=0.11 vs controls).
AE37 is an HER2 (aa 776–779)-derived peptide modified 
with a “li-Key” motif in order to elicit a combined CD4+ T- and 
CD8+ T-cell response.28 This vaccine  formulation was tested 
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at three different doses with or without GM-CSF in 15 patients 
with node-negative BC, in remission after standard therapy. 
Intriguingly, without adjuvants, AE37 was able to effectively 
elicit a specific combined response.65–67
Another HER2-derived peptide tested in clinical trials is 
GP2. This is a nine-aa, HLA-A2-restricted peptide derived 
from the transmembrane domain of HER2 (aa 654–662), 
with a lower affinity to HLA-A2.68 Preliminary results of a 
Phase II trial of the GP2 vaccine with GM-CSF were recently 
presented.69 In this trial, 172 HLA-A2-positive newly diag-
nosed women with node-positive or high-risk node-negative 
disease after standard therapy were enrolled. GP2 was shown 
to be able to elicit strong immunologic response in the vac-
cinated group, and, although not statistically significant, the 
immune response correlated with a .50% reduction in BC 
recurrences (4.3% vs 11.6% in the vaccine and control group, 
respectively; P=0.41).
Results of the clinical trials of anti-HER2 vaccines, using 
different types of platforms, are summarized in Table 3.70–73
Anti-MUC-1 and anti-CEA vaccines
MUC-1 is a membrane glycoprotein expressed by many 
types of epithelial cells, including breast, lung, and the 
gastrointestinal tract.74 In cancer cells, it is overexpressed 
and aberrantly  glycosylated, and involved in cell-to-cell 
and cell-to-matrix adhesion, in signal transduction, and in 
modulation of the immune system. Nearly 70% of cancers 
overexpress MUC-1.74,75 It has been demonstrated that 
MUC-1 can be immunogenic and could be a suitable target 
for cancer immunotherapy.76–78
A series of pilot studies using anti-unglycosylated MUC-1 
peptide-based vaccination were undertaken, with conflicting 
results.79–83 Further studies showed that directing immuno-
logic response against glycosylated form of MUC-1 could 
translate into stronger humoral responses. An anti-MUC-1 
vaccination conjugated with keyhole limpet hemocyanin 
(KLH) was shown to elicit strong humoral response and to 
be safe.84–86 Based on these results, Miles et al conducted 
a Phase III trial in 1,028 women with metastatic BC who 
had previously received chemotherapy and had had either a 
complete or a partial response, or no disease  progression.86 
All women received T-Reg-depleting doses of cyclophosph-
amide (300 mg/m2) 3 days before vaccine  injection. Although 
the treatment was well tolerated and able to induce strong 
humoral response, no DFS or overall survival (OS) benefit 
emerged.3 However, in patients treated with concomitant 
hormone therapy (34%), a trend toward improved time to 
progression and OS was observed. This observation suggests 
that combined therapy with anti-estrogens and  anti-MUC-1 
could be beneficial.
It was shown that most of the immunogenicity of MUC-1 
resided in a repeated 20-aa peptide domain in the extracel-
lular portion of the protein. This peptide, fused with oxidized 
mannan (M-FP) in an attempt to improve APC presentation, 
was able to induce both cytotoxic and humoral responses.87–90 
Hence, a pilot Phase III study in early stage BC patients 
using oxidized mannan–MUC-1 was undertaken.91 In this 
small, placebo-controlled, randomized study, 31 patients 
with stage II and no more than four lymph nodes involved 
were injected with the vaccine after surgery, radiotherapy, 
Table 3 Clinical trials with anti-HeR2 vaccinations
Platform Vaccine Setting  
and number  
of patients
Adverse events Results
Protein-based  
vaccine
HeR2 iCD + GM-CSF Adjuvant, 29 pts No G2, G3, or G4  
toxicities reported
Specific T-cell and antibody were elicited in 
89% and 82% of pts, respectively70
Protein-based  
vaccine
dHeR2 (truncated recombinant  
HeR2 eCD and iCD) +  
immunoadjuvant
Adjuvant, 45 pts One G3 fatigue  
and one G3 
neutropenia
HeR2 eCD and iCD antibodies developed  
after four immunizations 
Two pts showed evidence of tumor regression72
DNA-based vaccine Poxviral vector encoding  
a modified form of the HER2  
protein
Metastatic, 30 pts No G3 or G4  
toxicities reported
HER2-specific antibodies and T-cell response 
were detected in 66% pts (15 out of 28) 
evaluable patients had SD after 6 months FU71
whole cell-based  
vaccine
SKBR3 (HeR2 overexpressing  
cell line) genetically modified  
to secrete GM-CSF  
administered with TReg  
depleting doses of CY and DOX
Metastatic, 28 pts No G3 or G4  
toxicities reported
Induction of efficient immune response, 
including specific antibody production, 
enhanced by CY and DOX73
Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; eCD, extracellular domain; HeR2, human epithelial growth factor receptor 2; iCD, intracellular 
domain; pts, patients; G, grade; BC, breast cancer; MBC, metastatic breast cancer; FU, follow-up; SD, stable disease; TReg, regulatory T lymphocytes; CY, cyclophosphamide; DOX, 
doxorubicin; SKBR3, human HeR2 overexpressing breast cancer cell line.
Breast Cancer: Targets and Therapy 2014:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
164
Milani et al
and commencement of the adjuvant Tamoxifen. At 15 years 
of FU, the recurrence rate in patients receiving placebo was 
60% (9 out of 15), whereas in those receiving immunotherapy 
it was 12.5% (2 out of 16) (P=0.002).92 All patients injected 
with M-FP showed no evidence of toxic effects or signs of 
autoimmunity during the 12–15-year FU. No response to 
MUC-1 was seen in the patients treated with placebo, whereas 
9 of 13 patients immunized with MUC-1 had developed 
MUC-1-specific antibodies and 4 of 10 patients MUC-1-
specific T-cell responses. The clinical results obtained with 
this strategy are very promising, and further larger studies 
are warranted to confirm these results.
Carcinoembryonic antigen (CEA) is another glycoprotein 
aberrantly expressed in a multitude of cancer cell types, 
such as colorectal, lung, or breast cancer.93 It is a member 
of adhesion molecules, and its overexpression in cancer 
cells promotes their adhesion and the metastatic process.94 
PANVAC™ is a new cancer vaccine targeting both CEA and 
MUC-1. The vaccine is delivered through two sequential 
viral vectors, recombinant vaccinia (rV-) and recombinant 
fowlpox (rF-) – given in sequence, containing transgenes 
for the targets and for three human T-cell co-stimulatory 
 molecules (TRICOM [TRIad of COstimulatory Molecules]) 
to enhance immune system activation. The PANVAC vaccines 
are injected subcutaneously and processed by APCs.95 In a 
pilot study, 26 heavily pretreated patients with ovarian cancer 
or BC were enrolled. Side effects were largely limited to mild 
injection-site reactions. For the 12 BC patients enrolled, the 
median time to progression was 2.5 months and the median 
OS was 13.7 months. One patient had a complete response 
and remained on study for 37 months and another had partial 
response, whereas four patients had stable disease. Patient 
with fewer previous lines of treatment or low tumor burden 
were more likely to respond to the vaccine.96 In another pilot 
study, 25 patients with advanced metastatic carcinoma were 
treated with the vaccine. Two patients with BC were enrolled, 
one had a confirmed decrease of .20% in the size of large 
liver metastasis, whereas both had long-duration disease 
stabilization.97 These preliminary results show promising 
activity of this vaccine in BC, and further larger studies are 
currently going on.
Anti-hTERT vaccines
hTERT is another potential target for cancer vaccination. 
Telomerase is a ribonucleoprotein complex that maintains 
chromosomal integrity by protecting telomeric DNA for 
continuous cell proliferation.98 The complex contains hTERT 
and an RNA template. hTERT has broad expression in cancer 
cells, with little or no expression in normal somatic cells. 
A first pivotal study in 7 HLA-A2 advanced breast or prostate 
cancer patients showed good tolerability and promising clini-
cal efficacy. Patients enrolled in this study were vaccinated 
with autologous monocyte-derived DCs pulsed ex vivo with 
hTERT I540 peptide and KLH as adjuvant. Among the two 
patients with BC, one showed a mixed response of skin 
lesions, previously progressed despite chemo, hormonal, and 
radiotherapy.99 Another study was conducted on 19 HLA-A2-
positive patients with metastatic BC who were refractory to 
conventional therapy. Following vaccination, a specific CD8+ 
T-cell response was seen in more than 50% of the patients. 
Despite this, no objective responses were shown. However, 
in a post hoc analysis, it was shown that the median OS was 
significantly greater among patients with high CD8+ T-cell 
response than among low or no responders (32.2 months vs 
17.5 months, P=0.03).100
Combining BC vaccines  
with other strategies
Despite the encouraging preliminary results and excel-
lent profile of tolerability, BC vaccines still show limited 
clinical efficacy. Antigen variability and mechanisms of 
tumor immune-escaping can impair the effectiveness of 
active immunization. Moreover, possible difficulties of the 
immune effectors to reach poorly vascularized tumors and 
high tumor burdens may contribute to limit the efficiency 
of vaccines. For patients with larger burdens of tumor and 
disseminated disease, it is fairly clear that vaccines alone 
are not able to outmatch the immune tolerance mechanisms 
of cancer cells; moreover, these become progressively more 
complex with tumor progression. Thus, a possible way 
to overcome the known limits of active immunotherapy 
may be combining BC vaccines with other strategies, 
such as systemic BC therapies, passive immunotherapy, 
or immunomodulatory agents. Interaction of BC vac-
cines and systemic therapy could be complex and poorly 
predictable. Thus, any combinatorial strategy requires 
strong biologic rationale. For example, target-immune 
checkpoints and reducing activity of T-Regs could over-
come immune tolerance and increase the effectiveness of 
vaccination. Especially for patients with advanced disease, 
incorporating drugs that target BC-biology-inhibiting key 
intracellular signaling pathway may be required to enhance 
the activity of vaccines. In this field, results of first pivotal 
studies incorporating BC vaccines with targeted therapies 
have already been reported. Finally, disruption of tumor 
cells by conventional therapies could lead to the release of 
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tumor fragments/antigens that are otherwise not  accessible 
for presentation and processing and proinflammatory 
cytokines, with the final result of an increased immune 
response.
The humanized anti-HER2 monoclonal antibody tras-
tuzumab has been combined with an HER2 peptide-based 
vaccine in a Phase I/II study in 22 pretreated patients with 
HER2 overexpressing stage IV BC.101 The association treat-
ment was well tolerated and did not result in additional 
toxic effects. At a median FU of 36 months, the median 
progression free survival was 17.7 months (33% proportion 
of patients without events at 3 years). This finding favorably 
compares with the results obtained in similar settings by 
conventional treatments.
Patil et al102 recently reported preliminary results 
of a Phase I study of trastuzumab in combination with 
GP2 vaccine plus GM-CSF in an adjuvant setting. Nineteen 
patients were treated. The combination was shown to be safe, 
with only mild reaction at the site of injection. No adverse 
cardiac events were reported. The vaccine was shown to be 
highly immunogenic, and further studies on this combination 
are warranted.
Trastuzumab has also been safely combined with an 
HER2-positive, GM-CSF-secreting, allogeneic breast 
tumor-cell vaccine. Twenty-two patients with HER2-positive 
metastatic BC were enrolled in this study. No dose-limiting 
toxic effects were observed. Clinical benefit rates (com-
plete responses + partial responses + stable disease) at 
6 and 12 months were 50% (95% CI, 27%–72%) and 35% 
(95% CI, 15%–59%), respectively.103
A plasmid DNA encoding HER-2/neu together with low 
doses of GM-CSF and IL-2 and concurrent trastuzumab has 
been tested in eight patients with metastatic HER2-positive 
BC. The study was conducted by Norell et al.104 No relevant 
toxic effects were observed. The treatment was shown to 
induce immediate and strong antibody production along-
side long-lasting T-cell response. Notably, two out of six 
patients who completed all three vaccination cycles were 
long-term survivors, still alive more than 4 years after the 
last vaccination.
Finally, Hamilton et al105 published interesting results 
of a small pilot trial using recombinant anti-HER2 pro-
tein vaccine with concurrent Lapatinib in 12 women 
with trastuzumab-refractory HER2 overexpressing meta-
static BC. No unexpected adverse events were shown. 
Specific anti-HER2 humoral response was induced in all 
patients. Interestingly, OS at 300 days was 92% (95% CI, 
77%–100%).
Conclusion and future perspectives
In recent years, outstanding progress has been achieved 
toward the cure of BC. More personalized therapies, 
molecularly targeted drugs, and a deeper understanding 
of the mechanisms of disease have allowed improving 
the prognosis of certain subtypes of tumor. In this rapidly 
changing scenario, there is a growing interest in develop-
ing an effective cancer vaccine. Unfortunately, none of the 
vaccine tested so far in clinical trials has turned out to be 
“practice changing.” Nevertheless, three important lessons 
can be drawn.
First, many vaccines elicit a measurable immunologic 
response, such as specific antibodies or specific CD8+ T-cells, 
but this response often has little or no impact on tumor 
growth. Engaging only one compartment of the immune 
system (eg, only cytotoxic response or humoral response) is 
probably not sufficient for an effective therapeutic vaccine. 
New vaccination strategies should therefore aim at eliciting 
a wide response, involving multiple immune effectors such 
as cytotoxic and antibody-secreting B-cells, innate immunity 
effectors, and memory cells. The underlying concept would 
be that a “complete” immunologic response may promote 
increased release of tumor cell fragments/antigens and 
proinflammatory cytokines, resulting in an immunologic 
virtuous cycle.
Second, the main barrier against vaccination is probably 
due to complex immuno-escaping mechanisms developed by 
cancer cells. Regulatory cells such as T-Regs and molecular 
immune checkpoints (eg, CTLA-4, PD1/PD1L) play crucial 
roles in maintaining self-tolerance, and tumors are able to 
exploit these elements to get protection from immune sys-
tem’s attack. New strategies based on blocking antibodies, 
recombinant forms of ligands, or receptors should be imple-
mented to block such modulatory checkpoints and strengthen 
the immune response, with promising initial translation into 
clinical setting. One of the most intriguing perspectives of 
these strategies is obviously their synergism with immuno-
therapy approaches such as cancer vaccines.
Third, patients with large tumor burden and very 
advanced disease, enrolled in most of the clinical trials on 
cancer vaccines, are also those who benefit less from cancer 
vaccines alone. In fact, as cancer progresses and spreads in 
spite of multiple lines of treatment, immune-tolerance mech-
anisms become more intricate and the immune system is less 
likely to counteract the tumor. Therefore, in these patients, 
 combining vaccine with established drugs targeting cancer 
biology, such as endocrine therapy, tyrosine receptor inhibi-
tors, or chemotherapy, is required to achieve satisfactory 
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clinical results. In conclusion, in order to maximize the 
likelihood of success, new BC vaccines should be devel-
oped by integrating a thorough  understanding of immune 
tolerance mechanisms and tested in well-designed clinical 
trials conducted in immunologically favorable settings. 
Moreover, an additional effort should be made to improve 
immunotherapy in the specific basal-like subtype, which 
requires novel therapeutic strategies more than luminal and 
HER2-positive types.
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